The U.S. IPO market is no longer frozen for life sciences companies; it is open, albeit selectively. A track record…
Read More →
Part One: When Knowledge Acquired Hands – I. An Old Theory Meets a New Kind of Machine – When the…
Read More →
The much-discussed California Invasion of Privacy Act (CIPA) amendment, SB 690, has been signed by Governor Gavin Newsom and will…
Read More →
Part One: When Knowledge Acquired Hands – I. An Old Theory Meets a New Kind of Machine – When the…
Read More →
A recent Pittsburgh trial serves as a stark reminder that even when jury selection has resulted in a seemingly favorable…
Read More →
In many cases involving the alleged negligence of an independent contractor we may think the liability analysis is simple: there…
Read More →
On May 11, 2026, the United Stated Court of Appeals for the Third Circuit issued an important published, precedential opinion…
Read More →
A life science company leaves a trail of public disclosures behind it. Until recently, piecing that trail together took real…
Read More →
On September 9, 2026, the Federal Bureau of Investigation (FBI) released its first-ever unclassified Cyber Strategy, organized around four pillars:…
Read More →
Our European Antitrust Team explores the European Commission’s new guidelines on the assessment of exclusionary abuses of dominance under Article…
Read More →